DPP-4 inhibitors, such as Sitagliptin, Saxagliptin, and Linagliptin, have been used since 2006 and are widely prescribed for managing type 2 diabetes mellitus. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.